Knowledge & Resources
Global Innovative Contracting analysis, opinion and insights from our experts and global payer network
U.S. Inflation Reduction Act (IRA) Update: Pharmaceutical Companies Challenge the Medicare Drug Price Negotiation Program
U.S. Inflation Reduction Act (IRA) Update: Pharmaceutical Companies Challenge the Medicare Drug Price Negotiation Program
Analysis showing orphan drug list prices significantly higher in the U.S. than in the E.U. prompts questions about future pricing considerations for gene therapies
An analysis of orphan drug prices in the US raises concerns over the sustainability of gene therapy costs. This article explores factors influencing US drug prices , the potential impact of new EU pharmaceutical legislation and how pressure to curb spiralling drug prices is falling on US policy makers.
Analysis: Lessons from Novartis’ Approach to Population Health Management & Innovative Financing Models
Novartis, leader in the Population Health Management approach to expanding patient access to medicines, initiated a program in collaboration with NHS England to reduce low-density lipoprotein levels in patients with atherosclerotic cardiovascular disease, targeting up to 300,000 patients over three years. While the approach has seen success, challenges persist in its implementation, including technical, mindset, and regulatory barriers.